Dec 24, 2025 8:00am EST Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Nov 14, 2025 4:05pm EST Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Oct 02, 2025 8:00am EDT Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
Sep 17, 2025 1:00am EDT Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
Sep 10, 2025 8:00am EDT Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
Aug 13, 2025 5:00pm EDT Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Jul 08, 2025 8:00am EDT Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
May 14, 2025 9:00am EDT Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Apr 15, 2025 8:30am EDT Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
